India

India allows compulsory licensing for Bayer's Nexavar. Does this raise a question about India's IP regime?

Current Voting

68%

32%

Survey Box

Ranbaxy Controversy

Will the Ranbaxy controversy end the Indian pharma dominion in the US market?

Send this article by email

X